读书笔记丨北京大学肿瘤医院郭军教授团队-中国黑色素瘤原创临床研究阶段汇总

● 中国原创黑色素瘤 ●

Original melanoma of China

J Clin Oncol（3篇），Ann Oncol（1篇），Clin Cancer Res（2篇），Eur J Cancer（2篇）

中国原创黑色素瘤

Chin J Cancer Res

Chin J Cancer Res A phase II study of fotem ustine plus Dacarbazine with Dendritic Cell Vaccines as first-Line therapy for Chinese patients with advanced acral lentiginous melanoma（2009）

Eur J Cancer

Eur J Cancer  A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients （2011）

J Clin Oncol

J Clin Oncol Phase II, open-label, single-arm trial of Imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification （2011）

Mol Ther

Mol Ther A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma （2012）

Clin Cancer Res

Clin Cancer Res Phase II randomized trial comparing high-dose IFN-α2b with Temozolomide plus Cisplatin as systemic adjuvant therapy for resected mucosal melanoma （2013）

Ann Oncol

Ann Oncol Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial (2017)

BMC Cancer

BMC Cancer Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study (2018)

Transl Oncol

Transl Oncol A Phase Ib study of Pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma (KEYNOTE-151) (2019)

J Clin Oncol

J Clin Oncol Axitinib in combination with Toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: An open-label phase IB trial (2019)

Eur J Cancer

Eur J Cancer Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma (2020)

Clin Cancer Res

Clin Cancer Res Safety, efficacy and biomarker analysis of Toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial (2020)

J Immunother Cancer

J Immunother Cancer Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study（2020）

J Clin Oncol

J Clin Oncol Randomized phase II study of Bevacizumab in combination with Carboplatin plus Paclitaxel in patients with previously untreated advanced mucosal melanoma (2021)

Front Oncol

Front Oncol Overall survival of patients with unresectable or metastatic BRAF V600-mutant acral/cutaneous melanoma administered dabrafenib plus trametinib: Long-term follow-up of a multicenter, single-arm phase IIa trial (2021)

整理者